Form 8-K AbbVie Inc. For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AbbVie updates 2026 EPS guidance after $291M IPR&D charge
July 6, 2026 4:14 PM EDTAbbVie (NYSE: ABBV) has disclosed a $291 million pre-tax acquired in-process research and development (IPR&D) and milestones expense for the second quarter of 2026, which the company says will reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.17.
The company noted that... More
